NCT06010537已完成早期 1 期
A Single-center, Randomized, Open-label, Single-dose Study of Polysaccharide Superparamagnetic Iron Oxide Injection in Healthy Subjects to Evaluate Magnetic Resonance Imaging in Multiple Dose Groups
适应症
干预措施
相关药物
试验速览
- 阶段
- 早期 1 期
- 状态
- 已完成
- 入组人数
- 4
- 试验地点
- 1
- 主要终点
- Adverse event rate
研究概览
简要总结
This is a contrast-enhanced magnetic resonance imaging (MRI) study conducted on a single-administration of polyglucose superparamagnetic iron oxide injection. Two dose groups are set up in this study, 2.5 mg/kg and 3 mg/kg, and two subjects in each group received the test drug for safety evaluation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Signing the informed consent form before the trial and fully understanding the content, process and possible adverse effects of the trial;
- •Be able to complete the study according to the requirements of the trial protocol;
- •Male subjects aged 18 to 40 years old (including the threshold);
- •Subjects weighing no less than 50 kilograms. Body mass index (BMI) = weight (kg)/height2 (m2), BMI within the range of 19~26 (including the critical value);
- •Health status: no mental abnormality, no history of cardiovascular system, nervous system, respiratory system, digestive system, urinary system, endocrine system and metabolic abnormalities;
- •Vital signs, physical examination, laboratory tests, electrocardiogram and imaging tests are normal or abnormal without clinical significance;
- •No pregnancy and voluntary use of effective contraception for at least 6 months from 2 weeks prior to dosing to the last use of the study drug.
排除标准
- •Previously suffered from neuropsychiatric, respiratory, cardiovascular, gastrointestinal, hematologic-lymphatic, hepatic or renal insufficiency, endocrine, or musculoskeletal disorders, or other diseases, and in the judgment of the investigator, the previous medical history may have an impact on the magnetic resonance imaging procedure, the quality of the images, or the safety of the subject;
- •Subjects with internal metal foreign bodies (dentures, contraceptive rings, metal implants, metal clips, etc.) and persons who are claustrophobic;
- •Those who are allergic to the study drug, its metabolites or its excipients;
- •Subjects who have smoked more than 5 cigarettes per day for 3 months prior to the trial;
- •History of drug and/or alcohol abuse (14 units of alcohol per week: 1 unit = 360 ml of beer or 45 ml of spirits of 40% alcohol or 150 ml of wine);
- •Blood donation or significant blood loss (> 450 ml) within 2 months prior to dosing;
- •Use of any drug that alters liver enzyme activity (e.g., liver enzyme inhibitors chlorpromazine, cimetidine, ciprofloxacin, metronidazole, etc.; liver enzyme inducers barbiturates, carbamazepine, rifampicin, dexamethasone, etc.) in the 28 days prior to dosing;
- •Use of any prescription medication, over-the-counter medication, any vitamin product or herbal remedy within 14 days prior to dosing;
- •The need to use tobacco, alcohol and caffeinated beverages, or certain foods that may affect metabolism (e.g., grapefruit, grapefruit juice, etc.) during the trial period, or a significant change in dietary or exercise habits prior to the trial, or any other factor that affects the absorption, distribution, metabolism, or excretion of the drug;
- •Use of an investigational drug or participation in a clinical trial of a drug within 2 months prior to dosing;
- •Screening positive for hepatitis (including hepatitis B and C) and for AIDS and syphilis;
- •Screening positive for drugs or a history of drug abuse within the past 5 years or drug use within the 3 months prior to the trial;
- •Persons who have difficulty with MRI scanning or who cannot tolerate MRI scanning;
- •Acute illness occurring during the pre-study screening phase or prior to study drug administration;
- •Subjects who are unable or incapable of complying with ward regulations.
- •The subject is unable to complete the trial for personal reasons.
- •Other circumstances which, in the judgment of the investigator, make enrollment in the study unsuitable.
研究组 & 干预措施
polyglucose superparamagnetic iron oxide injection 2.5 mg/kg
Experimental
Intravenous injected polysaccharide superparamagnetic iron oxide injection at 2.5 mg/kg dose;
干预措施: polysaccharide superparamagnetic iron oxide injection (Drug)
polyglucose superparamagnetic iron oxide injection 3.0 mg/kg
Experimental
Intravenous injected polysaccharide superparamagnetic iron oxide injection at 3.0 mg/kg dose;
干预措施: polysaccharide superparamagnetic iron oxide injection (Drug)
结局指标
主要结局
Adverse event rate
时间窗: Baseline up to 144 hours
The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs).
次要结局
- Contrast-enhanced magnetic resonance angiography (CE-MRA)(Before administration, 5 minutes, 12 hours, 24 hours, 36 hours, 48 hours after administration.)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
Unknown
An advanced MRI-based, single-centre investigation of high grade gliomasACTRN12624001014549niversity of Newcastle30
进行中（未招募）
2 期
Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain MetastasesNCT06777433Radiopharm Theranostics, Ltd30
终止
1 期
This is a Single Ascending Dose Tolerance StudyCognition DisordersNCT01133574Abbott47
招募中
1 期
A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic CancerPancreatic CancerNCT06758544Guangdong Provincial People's Hospital18
已完成
1 期
A Study Investigating the Bioavailability of a High Concentration Liquid Formulation Versus a Reference Lyophilized Formulation of Gantenerumab in Healthy VolunteersHealthy VolunteerNCT02133937Hoffmann-La Roche31